It has been shown that RANTES-CCR5 axis plays a key role in the invasiveness of basal breast cancer cells and that CCR5 antagonists (such as maraviroc or vicriviroc, both HIV drugs) blocked tumor invasiveness in-vitro and efficiently reduced metastatic colonization in-vivo[62]. Here, CCL5 is linked to breast carcinoma.